Active Biotech and Teva has Submitted an IND to the FDA

Active Biotech AB and Israeli Teva Pharmaceutical Industries Ltd have announced the submission of an investigational new drug application, IND, to the FDA to initiate a clinical trial in the US with laquinimod to assess drug-drug interaction. Based on the results of this study and of the ongoing phase IIb study in Europe, the phase III clinical program to confirm the efficacy and safety of laquinimod in relapsing forms of multiple sclerosis, MS, is planned to start in 2006.

Laquinimod is a novel orally administered immunomodulatory substance, developed by Active Biotech and recently licensed to Teva.

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. The most advanced projects are laquinimod, an orally administered small molecule with unique immunemodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer.

For further information please contact:

Sven Andréasson

President and CEO

Tel: +46 (0) 46 19 20 00

Email: sven.andreasson@activebiotech.com

Or visit: http://www.activebiotech.com